It’s time to beat cancer

Vigeo is a clinical-stage biopharmaceutical company developing novel therapeutics that can effectively treat multiple types of cancer and improve the lives of patients.

Find Out More

We are building a first-in-class drug discovery pipeline that reprograms the tumor immune microenvironment (TIME). We believe that by reprogramming the TIME, we can significantly improve cancer treatment outcomes.


Vigeo is currently developing therapies that target the TIME by activating thrombospondin-1 (Tsp-1), a naturally occurring potent anti-tumorigenic protein, and one of the body’s own defenses against cancer. Tsp-1 has been shown to attack cancer cells and to prevent their spread through metastasis via CD36 and CD47 pathways.

Learn More

OUR <strong>APPROACH</strong>

Our clinical

We are currently studying VT1021, a peptide therapeutic agent in clinical trials enrolling patients in pancreatic, ovarian, triple negative breast cancers, glioblastoma, and tumors with high amounts of CD36.

Working at

Find out more about a career at Vigeo


Latest News

July 06, 2022

Global Coalition for Adaptive Research, Biohaven, and Vigeo Announce Commencement of Biohaven’s Troriluzole and Vigeo’s VT1021 in GBM Agile Trial

Read More »

January 20, 2022

Vigeo Therapeutics Advances VT1021 Into Phase 2-3 Registrational Study for Glioblastoma

Read More »

November 16, 2021

Vigeo Therapeutics Announces New Phase 1/2 Data from its Expansion Study of VT1021 at the Society of NeuroOncology’s 2021 Annual Meeting

Read More »